Weather, Weathering, Weathered: Editors\u27 Notebook

Editorial introduction to The Goose Volume 17, Issue 1 (2018)

Exploring the Revenue Mix of Nonprofit Organizations -- Does it Relate to Publicness

Nonprofit organizations offer a wide range of goods and services and seek funding from a variety of revenue sources. Our working theory n this paper is that the sources of funding are related to the services a nonprofit provides - specifically whether services are public, private, or mixed in the nature of their benefits. Using multiple subfields from three major fields in the National Taxonomy of Exempt Entities (NTEE), this study divides nonprofits according to service type, and estimates the impact of service character on particular revenue streams and overall level of revenue diversification. Generally, the proportion of revenues generated by program fees is lowest for the category deemed public, highest for those with mostly private benefits, and midway for "mixed" services which are private in character but entail substantial public benefits. Similarly, the more public a nonprofit's services, the greater the proportion of revenues it generates through donations. However, we also identify some puzzling results that suggest the need for continued investigation of the determinants of the sources and mixes of nonprofit income. Working Paper 07-3

Nagorno-Karabakh: Is it time to bring peacekeeping and confidence building back on the agenda? EPC Discussion Paper, 29 September 2016

The “four-day war”, fought between the Armenian and Azerbaijani armed forces from 1-5 April 2016, has forced the international community to take a fresh look at the Nagorno-Karabakh conflict. Although the fighting ended with a truce reached under Russia’s auspices, it showed the threat for further escalation and violence to be very real, raising the stakes for both sides in the conflict, and for the international community. In this Discussion Paper, Amanda Paul and Dennis Sammut discuss the latest developments in the Nagorno-Karabakh conflict, and argue that, with prospects of a resolution once more on the horizon, it is important that the momentum of any breakthrough is quickly consolidated. Peacekeeping and confidence building are an essential part of this process and the international community, most particularly the EU, must move fast to ensure that such measures are in place as soon as they are needed

The EU cannot remain a passive observer of the Karabakh conflict. EPC Commentary, 7 April 2016

When Federica Mogherini visited the South Caucasus in March, she was quoted as saying that the Nagorno-Karabakh conflict was a top priority for the EU. Facts, however, do not seem to match the words of the EU High Representative for Foreign Affairs and Security Policy. As violent clashes in the conflict zone unfolded over the past week, the EU was a passive observer, with few visible signs of engagement apart from a cursory phone call urging Armenia and Azerbaijan to show restraint. The escalation has shown how quickly and dangerously the situation can develop, and the unassailable nature of the Line of Contact (LoC). If the diplomatic efforts to resolve the conflict show no progress, a repetition is very probable. Furthermore, it is likely the next incident will be more devastating in human and material costs than this recent one, and may not be contained so quickly. The EU needs to be part of the renewed diplomatic effort

Nagorno-Karabakh and the arc of crises on Europe's borders. EPC Policy Brief, 3 February 2016

For more than two decades, Azerbaijan and Armenia have been locked in a stalemate over the Nagorno-Karabakh. The protracted conflict remains the biggest impediment to security, stability and prosperity in the South Caucasus. The EU has put itself on the sidelines of the conflict resolution process, allowing the Organization for Security and Co-operation in Europe (OSCE) Minsk Group (MG), of which Russia, France and the US are co-chairs, to take centre stage. In this Policy Brief, Amanda Paul and Dennis Sammut argue that the EU should play a more active role in the conflict resolution process, taking the lead with innovative initiatives and using its soft power skills and experience. A recent review of the European Neighbourhood Policy recognises that protracted conflicts continue to hamper development in the region. This new approach now needs to be given substance, before the conflict further escalates and becomes another crisis on Europe’s border the already burdened Union cannot cope with

Editors\u27 Notebook

Editorial introduction to The Goose Volume 16, Issue 2 (2018)

Armenia’s “Velvet Revolution”: Time is Pashinyan’s worst enemy. EPC Commentary, 30 May 2018

Nikol Pashinyan’s meteoric rise to the leadership of Armenia has happened unexpectedly. Widespread discontent with the administration of former president Serzh Sargsyan, youth's frustration with corrupt practices, and Pashinyan's sheer audacity turned what looked like an impossible task into a reality. A protest movement that started quite modestly in late March, focusing primarily on trying to block the appointment of Sargsyan as the country's new prime minister with full executive powers, eventually forced the governing Republican Party of Armenia (RPA) to acquiesce to Pashinyan's demands

Observations of the low-lying Ω = 1/2 states of nickel deuteride, NiD

International audienc

The Development of Orphan Drugs; A Financial and Ethical Decision

This paper explores the decision faced by a firm to invest in an orphan drug development project. Two primary areas of concern are considered: financial and ethical. In order to properly understand these two areas, the paper first summarizes the current development landscape for non-orphan and orphan drugs. Once the basic development structure is established, a discussion regarding the differences in the Net Present Value equation for a non-orphan and orphan product may occur. Once the differences in the financial decision are established, the paper will discuss the ethical considerations surrounding drug development and drug pricing. The combination of the financial model and the ethical guidelines for drug pricing form the argument for an increase in social corporate responsibility in the drug development industry to increase treatment accessibility for patients of rare diseases